Skip to main content
57th ASAM Annual Conference Main banner
Final Program


Preview Program
Feedback

Focus Session

Low-Threshold Injectable PrEP in People Who Use Drugs

Friday, April 24, 2026
1:30 PM - 2:45 PM PT
Location: Regatta, Level 4
Long-acting injectable PrEP represents a breakthrough in HIV prevention for people who use drugs, offering new opportunities for low-threshold, integrated care. This session combines didactic updates with real-world implementation lessons from leading programs across addiction medicine and harm reduction to help participants translate innovation into clinical practice.

Learning Objectives:

Learners will be able to:
  • Describe the pharmacology, dosing schedules, efficacy and safety of long‑acting injectable PrEP agents (cabotegravir and lenacapavir).
  • Identify key barriers and facilitators to PrEP access and uptake among people who use drugs, including structural, social and system‑level factors.
  • Discuss real‑world models for integrating low‑threshold injectable PrEP into harm‑reduction and addiction‑medicine settings (including pregnant/postpartum populations).
Disclosure(s):
Ethan Cowan, MD, MS: Gilead: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Indivior, LLC: CEC committee (Ongoing), Consultant/Advisory Board (Ongoing)
Ruchi M. Fitzgerald, MD, FAAFP FASAM: No financial relationships to disclose
Francesco Tani, DO: No financial relationships to disclose
Cayse M. Powell, MD, MPH: No financial relationships to disclose